General Biologicals (ROCO:4117) Other Current Payables: NT$79.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4117 General Biologicals Corp ROCO:4117
46 GF Score
Price NT$10.45
GF Value NT$14.00
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is General Biologicals Other Current Payables?

General Biologicals ROCO:4117 +0.97% 46 Other Current Payables is NT$79.8 Mil as of Dec. 2025. GuruFocus rates ROCO:4117 with a GF Score™ of 46/100 and a GF Value™ of NT$14.00 (Modestly Undervalued). The stock has 8 warning signs investors should review.

General Biologicals's Other Current Payables for the quarter that ended in Dec. 2025 was NT$79.8 Mil.

General Biologicals's quarterly Other Current Payables declined from Dec. 2024 (NT$52.3 Mil) to Jun. 2025 (NT$31.6 Mil) but then increased from Jun. 2025 (NT$31.6 Mil) to Dec. 2025 (NT$79.8 Mil).

General Biologicals's annual Other Current Payables declined from Dec. 2023 (NT$814.9 Mil) to Dec. 2024 (NT$52.3 Mil) but then increased from Dec. 2024 (NT$52.3 Mil) to Dec. 2025 (NT$79.8 Mil).

General Biologicals Other Current Payables Related Terms

General Biologicals Other Current Payables Historical Data

* Premium members only.

The historical data trend for General Biologicals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

General Biologicals Other Current Payables Chart

General Biologicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.81 46.20 814.93 52.34 79.77

General Biologicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 814.93 85.93 52.34 31.57 79.77
ROCO:4117
46GF Score
General Biologicals Corp ROCO:4117
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

General Biologicals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$79.8 Mil mean?
General Biologicals (ROCO:4117) has a Other Current Payables of NT$79.8 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on General Biologicals and its competitors.
Is General Biologicals' Other Current Payables too high?
General Biologicals' current Other Current Payables is NT$79.8 Mil. Overall, General Biologicals has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' Other Current Payables compare to ZTS?
General Biologicals' Other Current Payables of NT$79.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on General Biologicals and its competitors. General Biologicals's current Other Current Payables is NT$79.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.00, compared to a current price of NT$10.45 — trading 25.4% below its estimated fair value. The current Other Current Payables is NT$79.8 Mil. General Biologicals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current Other Current Payables is NT$79.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is General Biologicals (ROCO:4117) Overvalued in 2026?

Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued. The current stock price of NT$10.45 is trading 25.4% below its estimated GF Value™ of NT$14.00. GuruFocus considers General Biologicals to be Modestly Undervalued.

Key valuation signals for ROCO:4117:

  • Other Current Payables: NT$79.8 Mil
  • GF Value™: NT$14.00 vs. price of NT$10.45 (25.4% below fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

General Biologicals Business Description

Address No-6, Innovation First Road, Hsinchu Science Park, Hsinchu, TWN, 300092
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
46GF Score

Get the complete analysis for ROCO:4117

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.45
Price
NT$14.00
GF Value